Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus G Dalgleish

Showing results (21-30 of 83) with videos related to

Pageof 9
Sort By:
Nature Reviews. Cancer|April 2, 2004
The evolution of thalidomide and its IMiD derivatives as anticancer agentsJ Blake Bartlett, Keith Dredge, Angus G Dalgleish
Scientific Reports|February 9, 2019
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cellsAndrew M Gravett, Angus G Dalgleish, John Copier
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Angiogenesis inhibitors in cancer therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Medical Oncology (Northwood, London, England)|May 13, 2009
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case studyWai M Liu, Shiyam Nizar, Angus G Dalgleish
Expert Opinion on Biological Therapy|January 9, 2003
Recent developments in antiangiogenic therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Critical Reviews in Immunology|June 14, 2003
Immunological effects of thalidomide and its chemical and functional analogsKeith Dredge, J Blake Marriott, Angus G Dalgleish
Anti-Cancer Drugs|June 5, 2003
Thalidomide analogs as emerging anti-cancer drugsKeith Dredge, Angus G Dalgleish, J Blake Marriott
Frontiers in Immunology|July 27, 2017
Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like ReceptorsRachel Cant, Angus G Dalgleish, Rachel L Allen
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|July 23, 2003
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agentsJ Blake Marriott, Keith Dredge, Angus G Dalgleish
International Journal of Oncology|June 1, 2017
Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administrationKatherine A Scott, Angus G Dalgleish, Wai M Liu
Pageof 9

Showing results (21-30 of 83) with videos related to

Sort By:
Pageof 9
Nature Reviews. Cancer|April 2, 2004
The evolution of thalidomide and its IMiD derivatives as anticancer agentsJ Blake Bartlett, Keith Dredge, Angus G Dalgleish
Scientific Reports|February 9, 2019
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cellsAndrew M Gravett, Angus G Dalgleish, John Copier
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Angiogenesis inhibitors in cancer therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Medical Oncology (Northwood, London, England)|May 13, 2009
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case studyWai M Liu, Shiyam Nizar, Angus G Dalgleish
Expert Opinion on Biological Therapy|January 9, 2003
Recent developments in antiangiogenic therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Critical Reviews in Immunology|June 14, 2003
Immunological effects of thalidomide and its chemical and functional analogsKeith Dredge, J Blake Marriott, Angus G Dalgleish
Anti-Cancer Drugs|June 5, 2003
Thalidomide analogs as emerging anti-cancer drugsKeith Dredge, Angus G Dalgleish, J Blake Marriott
Frontiers in Immunology|July 27, 2017
Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like ReceptorsRachel Cant, Angus G Dalgleish, Rachel L Allen
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|July 23, 2003
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agentsJ Blake Marriott, Keith Dredge, Angus G Dalgleish
International Journal of Oncology|June 1, 2017
Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administrationKatherine A Scott, Angus G Dalgleish, Wai M Liu
Pageof 9